生物活性 | |||
---|---|---|---|
靶点 |
|
||
描述 | Autophagy, the sequestration of organelles and proteins in autophagic vesicles (AVs) and degradation of this cargo through lysosomal fusion, allows tumor cells to survive metabolic and therapeutic stresses[2]. Lys05, a dimeric chloroquine, is a new lysosomal autophagy inhibitor which more potently accumulates in the lysosome and blocks autophagy compared with hydroxychloroquine (HCQ)[3]. C8161 xenografts matched for tumor size were treated with Lys05 (76 mg/kg; i.p.) for 48 h . Cells with intact nuclear and cytoplasmic membranes contained large AVs in Lys05-treated tumors. Meanwhile, significantly higher LC3II/LC3I levels were observed in Lys05-treated tumors compared with control- or HCQ-treated tumors, providing further evidence of in vivo autophagy inhibition. Mice bearing 1205Lu xenografts matched for tumor volume were treated with Lys05 (76 mg/kg; i.p.) and dosed for 3 d of daily treatment with 2 d off treatment. Lys05 treatment resulted in a 53% reduction in the average daily tumor growth rate compared with vehicle-treated controls. A significant six-fold accumulation of AV was observed at the end of 14 d of treatment in Lys05-treated tumors, compared with control group. Extensive tumor necrosis was observed in Lys05-treated tumors[2]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.82mL 0.36mL 0.18mL |
9.10mL 1.82mL 0.91mL |
18.19mL 3.64mL 1.82mL |
参考文献 |
---|